Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib

Neuro-Oncology

Volumn 12, Issue 5, 2010, Pages 466-472

  Gerstner, Elizabeth R ^a   Chen, Poe Jou ^c   Wen, Patrick Y ^a,b   Jain, Rakesh K ^a   Batchelor, Tracy T ^a   Sorensen, Gregory ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

ADC; Antiangiogenic therapy; Diffusion MRI; Glioma; Infiltration

Indexed keywords

CEDIRANIB; 4 ((4 FLUORO 2 METHYL 1H INDOL 5 YL)OXY) 6 METHOXY 7 (3 (PYRROLIDIN 1 YL)PROPOXY)QUINAZOLINE; 4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-(3-(PYRROLIDIN-1-YL)PROPOXY)QUINAZOLINE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER RECURRENCE; CELL INFILTRATION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; GLIOBLASTOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; BRAIN TUMOR; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; DISEASE FREE SURVIVAL; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE-FREE SURVIVAL; GLIOBLASTOMA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES;

EID: 77954730533     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop051     Document Type: Article

References (24)

1. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83-95
2. Cloughesy TF, Prados MD, Wen PY, et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol. 2008; 26 (suppl): abstract 2010b
3. Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK. Response criteria for glioma. Nat Clin Pract Oncol. 2008;5:634-644
4. Hesselink JR, Press GA. MR contrast enhancement of intracranial lesions with Gd-DTPA. Radiol Clin North Am. 1988;26:873-887
5. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000;2:306-314
6. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001;61:6624-6628
7. McConville P, Hambardzumyan D, Moody JB, et al. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res. 2007;13:2897-2904
8. Hall DE, Moffat BA, Stojanovska J, et al. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res. 2004;10:7852-7859
9. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92:2029-2036
10. Chenevert TL, Sundgren PC, Ross BD. Diffusion imaging: insight to cell status and cytoarchitecture. Neuroimaging Clin N Am. 2006;16: 619-632, viii-ix.
11. Thoeny HC, De Keyzer F, Chen F, et al. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology. 2005;234:756-764
12. Lee KC, Hall DE, Hoff BA, et al. Dynamic imaging of emerging resistance during cancer therapy. Cancer Res. 2006;66:4687-4692
13. Lazovic J, Jensen MC, Ferkassian E, Aguilar B, Raubitschek A, Jacobs RE. Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme. Clin Cancer Res. 2008;14:3832-3839
14. Chenevert TL, McKeever PE, Ross BD. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res. 1997;3:1457-1466
15. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280
16. Sorensen AG, Patel S, Harmath C, et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol. 2001;19:551-557
17. Gomez-Manzano C, Holash J, Fueyo J, et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol. 2008; 10:940-945
18. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8: 610-622
19. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70:779-787
20. Mardor Y, Pfeffer R, Spiegelmann R, et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol. 2003;21:1094-1100
21. Mardor Y, Roth Y, Lidar Z, et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. 2001;61: 4971-4973
22. Hamstra DA, Galban CJ, Meyer CR, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008;26:3387-3394
23. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA. 2005;102:16759-16764
24. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA. 2005;102: 5524-5529